RAPP Rapport Therapeutics, Inc.
Price Chart
Executive Summary
Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 on May 27, 2026, indicating intent to sell 18,572 shares of Rapport Therapeutics common stock, valued at approximately $742,880. The selling entity has been actively reducing its position, with four prior sales totaling ~836,136 shares in the past month, signaling continued distribution by a major insider.
Actionable Insight
Third Rock Ventures continues to systematically reduce its stake, with over $70M in sales in the past month. This persistent selling by a top-10 holder creates overhang and signals diminishing conviction. Monitor for further 144 filings and potential acceleration of sales ahead of any upcoming catalysts or lock-up expirations.
Key Facts
- Third Rock Ventures V, L.P. (10% stockholder) filed Form 144 to sell 18,572 shares of RAPP common stock.
- Estimated value of proposed sale: $742,880.
- Selling entity has sold ~836,136 shares in four separate transactions between April 17 and May 11, 2026, totaling ~$70.6 million.
- Form 144 filed on May 27, 2026; proposed sale date listed as May 26, 2026.
- Total shares outstanding referenced: 47,826,929.
Financial Impact
Proposed sale of $742,880 represents ~0.04% of market cap; however, cumulative insider sales by Third Rock Ventures over the past month exceed $70 million.
Risk Factors
- Continued insider selling by a major stockholder may pressure the stock.
- Potential for additional unregistered sales if the entity files further 144 notices.
- Selling ahead of clinical data or earnings could indicate negative non-public information.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001974078-26-000199 |
| Document: 0001974078-26-000199-index.html | 0001974078-26-000199 |
| Document: 0001974078-26-000199.txt | 0001974078-26-000199 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $35.19 awaiting T+5 | awaiting T+5 | — | $38.40 (+9.12%) |
|
May 27, 2026
17d ago
|
144
| $39.51 $34.90 | ▲ +11.67% | ▲ +12.88% | $38.40 (+2.81%) |
|
May 11, 2026
4w ago
|
144
| $37.24 $35.18 | ▲ +5.53% | ▲ +5.61% | $38.40 (−3.11%) |
|
May 8, 2026
5w ago
|
144
| $38.43 $35.18 | ▼ −8.46% | ▼ −8.37% | $38.40 (−0.08%) |
|
May 7, 2026
5w ago
|
144
| $38.04 $37.95 | ▼ −0.24% | ▼ −1.70% | $38.40 (+0.95%) |
|
May 7, 2026
5w ago
|
8-K
| $39.93 $38.08 | ▼ −4.63% | ▼ −6.14% | $38.40 (−3.83%) |
|
Apr 23, 2026
7w ago
|
DEFA14A
| $36.36 $33.00 | ▼ −9.24% | ▼ −10.72% | $38.40 (+5.61%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $36.78 $33.30 | ▼ −9.48% | ▼ −9.53% | $38.40 (+4.40%) |
|
Apr 1, 2026
10w ago
|
Press Release
| $31.67 $34.22 | ▲ +8.05% | ▲ +4.29% | $38.40 (+21.25%) |
|
Mar 30, 2026
10w ago
|
144
| $31.29 $33.69 | ▲ +7.67% | ▲ +3.73% | $38.40 (+22.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access